Cargando…
Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update
To update resource-stratified, evidence-based recommendations on secondary prevention of cervical cancer globally. METHODS: American Society of Clinical Oncology convened a multidisciplinary, multinational Expert Panel to produce recommendations reflecting four resource-tiered settings. A review of...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812449/ https://www.ncbi.nlm.nih.gov/pubmed/36162041 http://dx.doi.org/10.1200/GO.22.00217 |
_version_ | 1784863729060413440 |
---|---|
author | Shastri, Surendra S. Temin, Sarah Almonte, Maribel Basu, Partha Campos, Nicole G. Gravitt, Patty E. Gupta, Vandana Lombe, Dorothy C. Murillo, Rául Nakisige, Carolyn Ogilvie, Gina Pinder, Leeya F. Poli, Usha R. Qiao, Youlin Woo, Yin Ling Jeronimo, Jose |
author_facet | Shastri, Surendra S. Temin, Sarah Almonte, Maribel Basu, Partha Campos, Nicole G. Gravitt, Patty E. Gupta, Vandana Lombe, Dorothy C. Murillo, Rául Nakisige, Carolyn Ogilvie, Gina Pinder, Leeya F. Poli, Usha R. Qiao, Youlin Woo, Yin Ling Jeronimo, Jose |
author_sort | Shastri, Surendra S. |
collection | PubMed |
description | To update resource-stratified, evidence-based recommendations on secondary prevention of cervical cancer globally. METHODS: American Society of Clinical Oncology convened a multidisciplinary, multinational Expert Panel to produce recommendations reflecting four resource-tiered settings. A review of existing guidelines, formal consensus-based process, and modified ADAPTE process to adapt existing guidelines was conducted. Other experts participated in formal consensus. RESULTS: This guideline update reflects changes in evidence since the previous update. Five existing guidelines were identified and reviewed, and adapted recommendations form the evidence base. Cost-effectiveness analyses provided indirect evidence to inform consensus, which resulted in ≥ 75% agreement. RECOMMENDATIONS: Human papillomavirus (HPV) DNA testing is recommended in all resource settings; visual inspection with acetic acid may be used in basic settings. Recommended age ranges and frequencies vary by the following setting: maximal: age 25-65 years, every 5 years; enhanced: age 30-65 years, if two consecutive negative tests at 5-year intervals, then every 10 years; limited: age 30-49 years, every 10 years; basic: age 30-49 years, one to three times per lifetime. For basic settings, visual assessment is used to determine treatment eligibility; in other settings, genotyping with cytology or cytology alone is used to determine treatment. For basic settings, treatment is recommended if abnormal triage results are obtained; in other settings, abnormal triage results followed by colposcopy is recommended. For basic settings, treatment options are thermal ablation or loop electrosurgical excision procedure; for other settings, loop electrosurgical excision procedure or ablation is recommended; with a 12-month follow-up in all settings. Women who are HIV-positive should be screened with HPV testing after diagnosis, twice as many times per lifetime as the general population. Screening is recommended at 6 weeks postpartum in basic settings; in other settings, screening is recommended at 6 months. In basic settings without mass screening, infrastructure for HPV testing, diagnosis, and treatment should be developed. Additional information is available at www.asco.org/resource-stratified-guidelines. |
format | Online Article Text |
id | pubmed-9812449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-98124492023-01-05 Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update Shastri, Surendra S. Temin, Sarah Almonte, Maribel Basu, Partha Campos, Nicole G. Gravitt, Patty E. Gupta, Vandana Lombe, Dorothy C. Murillo, Rául Nakisige, Carolyn Ogilvie, Gina Pinder, Leeya F. Poli, Usha R. Qiao, Youlin Woo, Yin Ling Jeronimo, Jose JCO Glob Oncol SPECIAL ARTICLES To update resource-stratified, evidence-based recommendations on secondary prevention of cervical cancer globally. METHODS: American Society of Clinical Oncology convened a multidisciplinary, multinational Expert Panel to produce recommendations reflecting four resource-tiered settings. A review of existing guidelines, formal consensus-based process, and modified ADAPTE process to adapt existing guidelines was conducted. Other experts participated in formal consensus. RESULTS: This guideline update reflects changes in evidence since the previous update. Five existing guidelines were identified and reviewed, and adapted recommendations form the evidence base. Cost-effectiveness analyses provided indirect evidence to inform consensus, which resulted in ≥ 75% agreement. RECOMMENDATIONS: Human papillomavirus (HPV) DNA testing is recommended in all resource settings; visual inspection with acetic acid may be used in basic settings. Recommended age ranges and frequencies vary by the following setting: maximal: age 25-65 years, every 5 years; enhanced: age 30-65 years, if two consecutive negative tests at 5-year intervals, then every 10 years; limited: age 30-49 years, every 10 years; basic: age 30-49 years, one to three times per lifetime. For basic settings, visual assessment is used to determine treatment eligibility; in other settings, genotyping with cytology or cytology alone is used to determine treatment. For basic settings, treatment is recommended if abnormal triage results are obtained; in other settings, abnormal triage results followed by colposcopy is recommended. For basic settings, treatment options are thermal ablation or loop electrosurgical excision procedure; for other settings, loop electrosurgical excision procedure or ablation is recommended; with a 12-month follow-up in all settings. Women who are HIV-positive should be screened with HPV testing after diagnosis, twice as many times per lifetime as the general population. Screening is recommended at 6 weeks postpartum in basic settings; in other settings, screening is recommended at 6 months. In basic settings without mass screening, infrastructure for HPV testing, diagnosis, and treatment should be developed. Additional information is available at www.asco.org/resource-stratified-guidelines. Wolters Kluwer Health 2022-09-26 /pmc/articles/PMC9812449/ /pubmed/36162041 http://dx.doi.org/10.1200/GO.22.00217 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | SPECIAL ARTICLES Shastri, Surendra S. Temin, Sarah Almonte, Maribel Basu, Partha Campos, Nicole G. Gravitt, Patty E. Gupta, Vandana Lombe, Dorothy C. Murillo, Rául Nakisige, Carolyn Ogilvie, Gina Pinder, Leeya F. Poli, Usha R. Qiao, Youlin Woo, Yin Ling Jeronimo, Jose Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update |
title | Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update |
title_full | Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update |
title_fullStr | Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update |
title_full_unstemmed | Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update |
title_short | Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline Update |
title_sort | secondary prevention of cervical cancer: asco resource–stratified guideline update |
topic | SPECIAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812449/ https://www.ncbi.nlm.nih.gov/pubmed/36162041 http://dx.doi.org/10.1200/GO.22.00217 |
work_keys_str_mv | AT shastrisurendras secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT teminsarah secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT almontemaribel secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT basupartha secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT camposnicoleg secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT gravittpattye secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT guptavandana secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT lombedorothyc secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT murilloraul secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT nakisigecarolyn secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT ogilviegina secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT pinderleeyaf secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT poliushar secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT qiaoyoulin secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT wooyinling secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate AT jeronimojose secondarypreventionofcervicalcancerascoresourcestratifiedguidelineupdate |